A Study to Analyze Intramyocardial Injection Mononuclear Cells during Fontan Surgical Palliation of Congenital Heart Disease

Overview

Información sobre este estudio

This study aims to evaluate the safety of intramyocardial delivery of autologous umbilical cord blood-derived mononuclear cells during Fontan surgical palliation and measure surrogate markers of myocardial protection within a non-randomized study design to obtain prospective data from treatment and control populations.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Diagnosis of a congenital heart defect with functionally single right ventricle (such as HLHS, HLHS variants, unbalanced AV septal defect with RV dominance, DORV with Hypoplastic LV) undergoing Fontan surgical palliation.
  • At least 2 and less than or equal to 5 years of age at time of Fontan surgical palliation.
  • For subjects enrolling in the treatment arm, previous participation in clinical trial Umbilical Cord Blood Collection and Processing for Hypoplastic Left Heart Syndrome Patients (NCT01856049) with autologous UCB-MNC product collected and available for distribution is required.

Exclusion Criteria:

  • History of DMSO reaction (treatment arm only subjects).
  • Parent(s) or legal guardian unwilling to have their child participate or unwilling to follow the study procedures.
  • Severe chronic diseases at the discretion of the treating physician.
  • Extensive extra-cardiac syndromic features.
  • History of cancer.
  • Any of the following complications of his/her congenital heart disease:
    • Any condition requiring urgent, or unplanned interventional procedure within 15 days prior to Fontan surgical palliation, unless complete and full cardiac recovery is documented by site investigator.
    • Severe pulmonary hypertension (reported in the medical record as >70% systemic pressure).
    • Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome, not directly related to the stem cell product or its injection procedure, during or after Fontan surgical palliation.
  • Individuals with severe heart failure that requires heart transplantation.
  • Individuals with refractory or worsening arrhythmia.
  • Individuals with an automated implantable cardioverter defibrillator (AICD) or pacemaker.
  • Patients with prior surgical complications during the Fontan surgical palliation that resulted in or could be reasonably expected to significantly decrease cardiac function.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Joseph Dearani, M.D.

Cerrado para la inscripción

Contact information:

Karen Miller CCRP

(507) 266-5510

Miller.Karen1@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20522383

Mayo Clinic Footer